Geoff Hsu, manager of the Biotech Growth trust, tells Cherry Reynard why he is confident the well-performing sector has even further to run.
Healthcare has been one of the notable winners of the past 12 months, but nowhere more so than biotechnology. Long unloved in the nervous post-credit crisis environment, it has shot ahead since the start of this year, delivering, in many cases, triple digit returns. While all biotechnology funds have risen with this tide, the Biotech Growth trust, run by US healthcare specialists OrbiMed, has been the stand-out performer. Manager Geoff Hsu took over the trust in 2005 when OrbiMed changed the investment remit. Previously known as the Finsbury Life Sciences trust, the fund had been focu...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
